Clinical Scorecard: In Memoriam: Professor LU Daopei, Renowned Chinese Pioneer in Transplantation

At a Glance

Key Highlights

• Performed the first hematopoietic cell transplant in Asia in 1964 with a 60-year survivor outcome
• Pioneered the first HLA-haplotype-mismatched transplant in China in 1991, addressing donor limitations due to the one-child policy
• Founded key national registries and programs including the China Bone Marrow Transplant Registry and China Marrow Donor Program

Guideline-Based Recommendations

Diagnosis

• Utilize HLA typing to identify suitable donors including haplotype-mismatched options when matched siblings are unavailable

Management

• Implement hematopoietic cell transplantation as a curative approach for eligible leukemia patients
• Incorporate oral arsenic sulfide therapy for acute promyelocytic leukemia as pioneered by Prof. LU

Monitoring & Follow-up

• Long-term follow-up of transplant recipients to assess graft success and survival outcomes

Risks

• Consider risks related to donor mismatch and graft-versus-host disease in haplotype-mismatched transplants

Patient & Prescribing Data

Leukemia patients including those lacking matched sibling donors

Oral arsenic sulfide is an effective treatment for acute promyelocytic leukemia; hematopoietic cell transplantation outcomes have reached world-class levels under Prof. LU’s leadership

Clinical Best Practices

• Establish and utilize national donor registries and cord blood banks to expand transplant donor availability
• Adopt innovative transplant techniques such as haplotype-mismatched transplants to overcome donor shortages
• Provide comprehensive training and mentorship to cultivate expertise in hematology and transplantation

References

• Peking University Institute of Hematology
• Center for International Blood and Marrow Transplant Research (CIBMTR)